MoonLake shares crash 88% after mixed trial results raise doubts over skin drug

MoonLake Immunotherapeutics shares plummeted 88% after reporting mixed Phase 3 trial results for its skin drug, sonelokimab, with a high placebo response in one study raising doubts about its competitive efficacy. RBC Capital Markets downgraded the stock, citing uncompetitive effect size against rivals like UCB's Bimzelx, while Wedbush acknowledged significant stock pressure and shifted focus to regulatory approval. This outcome, alongside a wider-than-expected quarterly loss, is expected to impact the company's broader pipeline and cool prior acquisition interest.

Analysis

MoonLake Immunotherapeutics (MLTX) has experienced a catastrophic valuation collapse, with its shares falling 88% to $7.45 in premarket trading, following the release of mixed Phase 3 trial data for its lead asset, sonelokimab. The core issue stems from a higher-than-expected placebo response in one of its two pivotal studies for hidradenitis suppurativa, which obfuscated the drug's statistical significance and undermined its competitive profile. This has prompted a sharp divergence in analyst sentiment; RBC Capital Markets downgraded the stock to "Sector Perform" and slashed its price target from $67 to $10, citing placebo-adjusted results that were in their "worst case scenario" and uncompetitive against UCB's rival drug, Bimzelx. While Wedbush maintained an "Outperform" rating, it conceded the focus has shifted from sonelokimab's market differentiation to the more fundamental uncertainty of whether it can even secure regulatory approval. The clinical setback is compounded by significant financial and strategic repercussions. The data is expected to cool M&A interest, effectively removing the valuation floor implied by Merck's previously reported >$3 billion takeover approach, as the drug now appears potentially inferior to competitors. Furthermore, the company reported a wider-than-expected quarterly loss of $55.22 million ($0.87/share) against a consensus of $0.72/share, heightening financial pressure on the pre-revenue biotech and casting doubt on its broader pipeline, including a psoriatic arthritis study with data due in 2026.

Key Decisions for Investors

• The investment thesis for MoonLake, previously based on sonelokimab's best-in-class potential, is now fundamentally impaired; valuation must be reassessed on a high-risk, binary regulatory outcome with a severely diminished commercial profile.
• Investors should consider the acquisition premium, previously a key support for the stock's valuation, to be effectively eliminated given the data suggests inferiority to competing therapies, making a strategic buyout unlikely in the near term.
• Monitor the company's cash burn and balance sheet closely, as the wider-than-expected loss combined with the clinical setback significantly increases the risk of future dilutive financing to fund operations and the remaining pipeline.
• The key forward-looking catalyst is no longer market potential but regulatory feedback on the mixed data; any communication regarding a path to a Biologics License Application (BLA) submission will be a critical determinant of any remaining value.